Beskrywing

An orphan drug is a medicine for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition that is rare or where the medicine is unlikely to generate sufficient profit to justify research and development costs. They are orphans because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions. The global orphan drugs market is set to grow by US$ 69 miljard tydens 2021-2027, groei teen 'n saamgestelde jaarlikse groeikoers (CAGR) van 5.5% gedurende die voorspellingsperiode, volgens die data- en ontledingsmaatskappy StrategyHelix. Availability of exclusivity for orphan drugs, rising prevalence of rare diseases, favorable government policies are expected to boost the market growth in the coming years.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2017-2020 en voorspel tot 2027 covering key market aspects like sales value for orphan drugs. The global orphan drugs market is segmented on the basis of drug type, top selling drug, disease type, en streek. By drug type, it is categorized into biological drugs, and non-biological drugs. The biological drugs segment held the largest market share in 2020. By top selling drug, the orphan drugs market is divided into Revlimid, Tafinlar, Hemlibra, Darzalex, Kyprolis, Myozyme, Vyndaqel, Soliris, Ninlaro, Imbruvica, en ander. The Revlimid segment accounted for the largest market share in 2020. Based on disease type, the orphan drugs market is divided into oncology, blood disorders, central nervous system, respiratory system, immunomodulators, cardiovascular therapies, en ander.

The report has profiled some of the key players of the market such as AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Celgene Corporation, CSL Behring GmbH, Eisai Co. Bpk., F. Hoffmann-La Roche AG, Incyte Corporation, Jiangsu Hengrui Medicine Co. Bpk., Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi S.A., Syros Pharmaceuticals Inc., Takeda Pharmaceutical Co. Bpk., Vertex Pharmaceuticals Inc..

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the orphan drugs market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Drug type: biological drugs, and non-biological drugs
Top selling drug: Revlimid, Tafinlar, Hemlibra, Darzalex, Kyprolis, Myozyme, Vyndaqel, Soliris, Ninlaro, Imbruvica, en ander
Disease type: oncology, blood disorders, central nervous system, respiratory system, immunomodulators, cardiovascular therapies, en ander
Streek: Noord-Amerika, Asiatiese Stille-Oseaan, Europa, en Res van die Wêreld (RY)
Jare oorweeg: hierdie verslag dek die tydperk 2017 aan 2027

Sleutelvoordele vir belanghebbendes

Get a comprehensive picture of the global orphan drugs market
Identify regional strategies and strategic priorities on the basis of local data and analysis
Bepaal groeisektore en -neigings vir belegging
Understand what the future of the global orphan drugs market looks like
Identifiseer die mededingende landskap en geleentheidsvenster

INHOUDSOPGAWE

1. Markdefinisie
2. Navorsingsmetodologie
3. Markdata & Outlook
3.1 Markwaarde
3.2 Markwaarde Voorspelling
4. Orphan Drugs Market by Drug Type
4.1 Biological Drugs
4.2 Non-Biological Drugs
5. Orphan Drugs Market by Top Selling Drug
5.1 Revlimid
5.2 Tafinlar
5.3 Hemlibra
5.4 Darzalex
5.5 Kyprolis
5.6 Myozyme
5.7 Vyndaqel
5.8 Soliris
5.9 Ninlaro
5.10 Imbruvica
5.11 Ander
6. Orphan Drugs Market by Disease Type
6.1 Oncology
6.2 Blood Disorders
6.3 Central Nervous System
6.4 Respiratory System
6.5 Immunomodulators
6.6 Cardiovascular Therapies
6.7 Ander
7. Orphan Drugs Market by Region
7.1 Noord-Amerika
7.2 Asiatiese Stille-Oseaan
7.3 Europa
7.4 Res Van Die Wêreld (Ry)
8. Maatskappy profiele
8.1 AbbVie Inc.
8.2 Alexion Pharmaceuticals Inc.
8.3 Amgen Inc.
8.4 AstraZeneca plc
8.5 Biogen Inc.
8.6 BioMarin Pharmaceutical Inc.
8.7 Bristol-Myers Squibb Company
8.8 Celgene Corporation
8.9 CSL Behring GmbH
8.10 Eisai Co., Bpk.
8.11 F. Hoffmann-La Roche AG
8.12 Incyte Corporation
8.13 Jiangsu Hengrui Medicine Co., Bpk.
8.14 Johnson & Johnson
8.15 Novartis AG
8.16 Pfizer Inc.
8.17 Sanofi S.A.
8.18 Syros Pharmaceuticals, Inc.
8.19 Takeda Pharmaceutical Co. Bpk.
8.20 Vertex Pharmaceuticals, Inc.
9. Bylaag
9.1 Oor StrategyHelix
9.2 Vrywaring